Health Economics›Breast cancer›Metastatic or unresectable disease first-line

Metastatic or unresectable disease first-line

Breast cancer · 18 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 12 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pertuzumab and T-DM1 Variant #01	ERBB2	R 105 479	21d	15.2 mo	—	23	R 2 426 014 PFS proxy	—
THP (Docetaxel) Variant #01	ERBB2	R 78 650	21d	17.5 mo	57.1 mo	26	R 2 044 908 PFS proxy	6
nab-Paclitaxel and Trastuzumab Variant #01	ERBB2	R 70 557	28d	~4.2 mo	~25.0 mo	~5	~R 352 785 PFS proxy · indirect	2
Trastuzumab emtansine monotherapy Variant #01	ERBB2	R 41 405	21d	14.2 mo	—	21	R 869 503 PFS proxy	1
Capecitabine, Bevacizumab, Trastuzumab Variant #01	ERBB2	R 40 047	21d	—	—	—	—	—
Lapatinib and Paclitaxel (TL) Variant #01	ERBB2	R 39 897	28d	—	27.8 mo	—	—	1
Capecitabine and Lapatinib Variant #01	ERBB2	R 24 534	21d	~6.8 mo	~21.6 mo	~10	~R 245 345 PFS proxy · indirect	7
TCH (Paclitaxel) Variant #01	ERBB2	R 20 788	28d	11.1 mo	—	13	R 270 248 PFS proxy	1
TCyH (Docetaxel) Variant #01	ERBB2	R 17 123	21d	—	—	—	—	—
Paclitaxel and Trastuzumab (TH) Variant #01	ERBB2	R 16 575	21d	13.7 mo	24.0 mo	20	R 331 509 PFS proxy	8
Vinorelbine and Trastuzumab (VH) Variant #01	ERBB2	R 14 392	28d	14.8 mo	—	17	R 244 663 PFS proxy	1
Docetaxel and Trastuzumab (TH) and Pyrotinib Variant #01 Partial	ERBB2	R 13 197	21d	24.3 mo	—	36	R 475 082 PFS proxy	1
Carboplatin and Paclitaxel (CP) and Trastuzumab Variant #02	ERBB2	R 12 882	21d	10.7 mo	—	16	R 206 113 PFS proxy	1
Docetaxel and Trastuzumab (TH) Variant #01	ERBB2	R 12 507	21d	12.5 mo	40.8 mo	19	R 237 632 PFS proxy	9
ECH Variant #01	ERBB2	R 12 212	21d	—	25.1 mo	—	—	—
Capecitabine and Trastuzumab (XH) Variant #02	ERBB2	R 11 671	21d	9.9 mo	—	15	R 175 058 PFS proxy	2
ACH Variant #01	ERBB2	R 11 155	21d	—	25.1 mo	—	—	—
Trastuzumab monotherapy Variant #04	ERBB2	R 10 438	21d	—	—	—	—	2

18 of 18 regimens shown